文献速递肿瘤 PET/CT

局部进展期胃腺癌临床分期是否应常规行18F-FDG PET/CT

Should 18F-FDG PET/CT Be Routinely Performed in the Clinical Staging of Locally Advanced Gastric Adenocarcinoma?
PubMed 文献 · Clin Nucl Med · 2018-01-01

前瞻性研究纳入50例确诊局部进展期胃癌患者,比较18F-FDG PET/CT与增强CT等常规影像在临床管理中的作用。PET/CT与增强CT诊断转移的灵敏度分别为68%和100%特异度分别为100%和93%,两者均仅诊断15例腹膜转移中的6例。作者认为18F-FDG PET/CT推荐用于局部进展期胃癌分期,但不能替代腹腔镜排除腹膜转移。

要点

  • 18F-FDG PET/CT与增强CT诊断转移的灵敏度分别为68%和100%,特异度分别为100%和93%。
  • 增强CT和18F-FDG PET/CT均仅诊断15例确诊腹膜转移患者中的6例。
  • 18F-FDG PET/CT和增强CT对治疗管理的影响分别为24%和22%。

核心结论

  • 作者认为18F-FDG PET/CT推荐用于局部进展期胃癌分期。
  • 18F-FDG PET/CT和增强CT不能替代腹腔镜排除腹膜转移。
  • 延迟18F-FDG PET/CT图像在多数病例中显示18F-FDG摄取增加,提高局部进展期胃癌检出。
  • 18F-FDG摄取程度在本系列中是有意义的预后工具。

研究设计与样本

  • 前瞻性研究,2010年1月至2011年12月在本院纳入疑似局部进展期胃癌患者。
  • 所有病例均行18F-FDG PET/CT、增强CT、超声内镜和腹腔镜检查。
  • 18F-FDG按4.0 MBq/kg注射后1小时和2小时以胃为中心行标准全身PET/CT显像。
  • 结果由组织病理学或不可手术患者的影像随访确认。
  • 连续纳入50例确诊局部进展期胃癌患者(20例女性,30例男性),平均±标准差年龄65.7±12.1岁。

主要发现

  • Lauren分型:肠型24例,弥漫型26例。
  • 35例有区域淋巴结受累,22例有远处转移,其中腹膜转移15例、腹膜后淋巴结2例、纵隔淋巴结1例、肝转移3例、骨转移1例。
  • 印戒细胞癌患者18F-FDG摄取显著较低(P=0.001)。
  • SUVmax与肿瘤分级相关(P<0.05)。
  • 标准与延迟18F-FDG PET/CT及增强CT分别在30例患者中识别出24例、27例和28例局部进展期胃癌。

关键数值与推荐

  • 18F-FDG PET/CT检测转移的灵敏度和特异度分别为68%和100%。
  • 增强CT检测转移的灵敏度和特异度分别为64%和93%。
  • 增强CT和18F-FDG PET/CT均仅诊断15例确诊腹膜转移患者中的6例。
  • 18F-FDG PET/CT和增强CT对治疗管理的影响分别为24%和22%。
  • Kaplan-Meier生存曲线显示,以SUVmax阈值小于3.96分组,SUVmax与总生存显著相关(P=0.04)。

临床怎么用

  • 作者认为18F-FDG PET/CT推荐用于局部进展期胃癌分期。
  • 作者指出18F-FDG PET/CT和增强CT不能替代腹腔镜排除腹膜转移。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this study was to evaluate F-FDG PET/CT compared with conventional imaging techniques in the clinical management of patients with locally advanced gastric cancer (LAGC). METHODS: A prospective study between January 2010 and December 2011 in patients with suspected LAGC was conducted in our hospital. F-FDG PET/CT, contrast-enhanced CT (CECT), endoscopic ultrasound, and laparoscopy were performed in all cases. Standard whole-body F-FDG PET/CT images were obtained centered on the stomach at 1 and 2 hours after injection of 4.0 MBq/kg of F-FDG. Findings were confirmed by histopathology or by imaging follow-up in nonoperable patients. RESULTS: Fifty consecutive patients with confirmed LAGC (20 women, 30 men) with a mean ± SD age of 65.7 ± 12.1 years were included. Using Lauren classification, 24 patients were intestinal subtype, and 26 were diffuse subtype. Thirty-five patients with locoregional lymph node involvement and 22 with distant metastases were confirmed as peritoneal metastases (n = 15), retroperitoneal (n = 2) or mediastinal lymph nodes (n = 1), and liver (n = 3) or bone metastases (n = 1). Patients with signet ring carcinoma showed significantly less F-FDG uptake (P = 0.001). SUVmax correlated with tumor grading (P < 0.05). Standard and delayed F-FDG PET/CT and CECT images identified LAGC in 24, 27, and 28 of 30 patients, respectively. The sensitivity and specificity for F-FDG PET/CT and CECT to detect metastases were 68% and 100% and 64% and 93%, respectively. Contrast-enhanced CT and F-FDG PET/CT diagnosed only 6 of the 15 patients with confirmed peritoneal metastases. The impact in therapeutic management of F-FDG PET/CT and CECT was 24% and 22%, respectively. Kaplan-Meier survival curves for the LGAC showed a significant correlation between SUVmax and overall survival using an SUVmax threshold of less than 3.96 (P = 0.04). CONCLUSIONS: F-FDG PET/CT should be recommended for staging of LAGC; however, F-FDG PET/CT and CECT cannot replace laparoscopy to rule out peritoneal metastases. Delayed F-FDG PET/CT images show an increase of F-FDG uptake in most cases, improving LAGC detection. The grade of F-FDG uptake represents a significant prognostic tool in this series.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Perlaza P, Ortín J, Pagès M, et al. Should 18F-FDG PET/CT Be Routinely Performed in the Clinical Staging of Locally Advanced Gastric Adenocarcinoma? Clin Nucl Med. 2018. PMID: 29485442. doi:10.1097/RLU.0000000000002028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。